Allergic Rhinitis - Pipeline Review, H1 2020

April 2020 | 164 pages | ID: AEED02F29ACEN
Global Markets Direct

Abstracts

Allergic Rhinitis - Pipeline Review, H1 2020

SUMMARY

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Allergic Rhinitis - Pipeline Review, H1 2020, provides an overview of the Allergic Rhinitis (Respiratory) pipeline landscape.

Allergic rhinitis is an allergic reaction that happens when immune system overreacts to substances that is inhaled. An allergen is something that triggers an allergy. When a person with allergic rhinitis breathes in an allergen such as pollen, mold, animal dander, or dust, the body releases chemicals that cause allergy symptoms. Symptoms of allergic rhinitis include stuffy runny nose, sneezing, swollen eyelids, itchy mouth, throat, ears.

REPORT HIGHLIGHTS

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Allergic Rhinitis - Pipeline Review, H1 2020, provides comprehensive information on the therapeutics under development for Allergic Rhinitis (Respiratory), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Allergic Rhinitis (Respiratory) pipeline guide also reviews of key players involved in therapeutic development for Allergic Rhinitis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities/Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical and Discovery stages are 5, 5, 12, 9, 2, 10 and 2 respectively. Similarly, the Universities portfolio in Phase II and Preclinical stages comprises 5 and 5 molecules, respectively.

Allergic Rhinitis (Respiratory) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

SCOPE

• The pipeline guide provides a snapshot of the global therapeutic landscape of Allergic Rhinitis (Respiratory).
• The pipeline guide reviews pipeline therapeutics for Allergic Rhinitis (Respiratory) by companies and universities/research institutes based on information derived from company and industry-specific sources.
• The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
• The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
• The pipeline guide reviews key companies involved in Allergic Rhinitis (Respiratory) therapeutics and enlists all their major and minor projects.
• The pipeline guide evaluates Allergic Rhinitis (Respiratory) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
• The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
• The pipeline guide reviews latest news related to pipeline therapeutics for Allergic Rhinitis (Respiratory)

REASONS TO BUY

• Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
• Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
• Find and recognize significant and varied types of therapeutics under development for Allergic Rhinitis (Respiratory).
• Classify potential new clients or partners in the target demographic.
• Develop tactical initiatives by understanding the focus areas of leading companies.
• Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
• Formulate corrective measures for pipeline projects by understanding Allergic Rhinitis (Respiratory) pipeline depth and focus of Indication therapeutics.
• Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
• Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Contents

Introduction
Allergic Rhinitis - Overview
Allergic Rhinitis - Therapeutics Development
Allergic Rhinitis - Therapeutics Assessment
Allergic Rhinitis - Companies Involved in Therapeutics Development
Allergic Rhinitis - Drug Profiles
Allergic Rhinitis - Dormant Projects
Allergic Rhinitis - Discontinued Products
Allergic Rhinitis - Product Development Milestones
Appendix

List Of Tables

LIST OF TABLES

Number of Products under Development for Allergic Rhinitis, H1 2020
Number of Products under Development by Companies, H1 2020
Number of Products under Development by Companies, H1 2020 (Contd..1), H1 2020
Number of Products under Development by Universities/Institutes, H1 2020
Products under Development by Companies, H1 2020
Products under Development by Companies, H1 2020 (Contd..1), H1 2020
Products under Development by Companies, H1 2020 (Contd..2), H1 2020
Products under Development by Universities/Institutes, H1 2020
Number of Products by Stage and Target, H1 2020
Number of Products by Stage and Mechanism of Action, H1 2020
Number of Products by Stage and Route of Administration, H1 2020
Number of Products by Stage and Molecule Type, H1 2020
Allergic Rhinitis - Pipeline by Advagene Biopharma Co Ltd, H1 2020
Allergic Rhinitis - Pipeline by ALK-Abello AS, H1 2020
Allergic Rhinitis - Pipeline by Allovate LLC, H1 2020
Allergic Rhinitis - Pipeline by AOBiome LLC, H1 2020
Allergic Rhinitis - Pipeline by ASIT Biotech SA, H1 2020
Allergic Rhinitis - Pipeline by Chrysalis BioTherapeutics Inc, H1 2020
Allergic Rhinitis - Pipeline by CSPC Pharmaceutical Group Ltd, H1 2020
Allergic Rhinitis - Pipeline by Dobecure SL, H1 2020
Allergic Rhinitis - Pipeline by Emergo Therapeutics Inc, H1 2020
Allergic Rhinitis - Pipeline by GlaxoSmithKline Plc, H1 2020
Allergic Rhinitis - Pipeline by Glenmark Pharmaceuticals Ltd, H1 2020
Allergic Rhinitis - Pipeline by HAL Allergy BV, H1 2020
Allergic Rhinitis - Pipeline by Inimmune Corp, H1 2020
Allergic Rhinitis - Pipeline by Inmunotek SL, H1 2020
Allergic Rhinitis - Pipeline by JiangSu Qyuns Therapeutics Co Ltd, H1 2020
Allergic Rhinitis - Pipeline by Kolmar Korea Holdings Co Ltd, H1 2020
Allergic Rhinitis - Pipeline by Laboratorios LETI SL, H1 2020
Allergic Rhinitis - Pipeline by Link Health Group, H1 2020
Allergic Rhinitis - Pipeline by Marinomed Biotech AG, H1 2020
Allergic Rhinitis - Pipeline by Mitsubishi Tanabe Pharma Corp, H1 2020
Allergic Rhinitis - Pipeline by Navipharm Co Ltd, H1 2020
Allergic Rhinitis - Pipeline by Novartis AG, H1 2020
Allergic Rhinitis - Pipeline by Oneness Biotech Co Ltd, H1 2020
Allergic Rhinitis - Pipeline by Paradigm Biopharmaceuticals Ltd, H1 2020
Allergic Rhinitis - Pipeline by Regeneron Pharmaceuticals Inc, H1 2020
Allergic Rhinitis - Pipeline by Roxall Medizin GmbH, H1 2020
Allergic Rhinitis - Pipeline by Sam-A Pharm Co Ltd, H1 2020
Allergic Rhinitis - Pipeline by Sedor Pharmaceuticals LLC, H1 2020
Allergic Rhinitis - Pipeline by Shouyao Holding Co Ltd, H1 2020
Allergic Rhinitis - Pipeline by Siolta Therapeutics Inc, H1 2020
Allergic Rhinitis - Pipeline by Stallergenes Greer plc, H1 2020
Allergic Rhinitis - Pipeline by The Geneva Biotech Center SA, H1 2020
Allergic Rhinitis - Pipeline by United Biomedical Inc, H1 2020
Allergic Rhinitis - Pipeline by Vactech Oy, H1 2020
Allergic Rhinitis - Pipeline by Wolwo Pharma, H1 2020
Allergic Rhinitis - Pipeline by Wuhan Yicheng Biotechnology Co Ltd, H1 2020
Allergic Rhinitis - Dormant Projects, H1 2020
Allergic Rhinitis - Dormant Projects, H1 2020 (Contd..1), H1 2020
Allergic Rhinitis - Dormant Projects, H1 2020 (Contd..2), H1 2020
Allergic Rhinitis - Dormant Projects, H1 2020 (Contd..3), H1 2020
Allergic Rhinitis - Dormant Projects, H1 2020 (Contd..4), H1 2020
Allergic Rhinitis - Dormant Projects, H1 2020 (Contd..5), H1 2020
Allergic Rhinitis - Dormant Projects, H1 2020 (Contd..6), H1 2020
Allergic Rhinitis - Dormant Projects, H1 2020 (Contd..7), H1 2020
Allergic Rhinitis - Discontinued Products, H1 2020
Allergic Rhinitis - Discontinued Products, H1 2020 (Contd..1), H1 2020

List Of Figures

LIST OF FIGURES

Number of Products under Development for Allergic Rhinitis, H1 2020
Number of Products under Development by Companies, H1 2020
Number of Products under Development by Universities/Institutes, H1 2020
Number of Products by Top 10 Targets, H1 2020
Number of Products by Stage and Top 10 Targets, H1 2020
Number of Products by Top 10 Mechanism of Actions, H1 2020
Number of Products by Stage and Top 10 Mechanism of Actions, H1 2020
Number of Products by Routes of Administration, H1 2020
Number of Products by Stage and Routes of Administration, H1 2020
Number of Products by Molecule Types, H1 2020
Number of Products by Stage and Molecule Types, H1 2020

COMPANIES MENTIONED

Advagene Biopharma Co Ltd
ALK-Abello AS
Allovate LLC
AOBiome LLC
ASIT Biotech SA
Chrysalis BioTherapeutics Inc
CSPC Pharmaceutical Group Ltd
Dobecure SL
Emergo Therapeutics Inc
GlaxoSmithKline Plc
Glenmark Pharmaceuticals Ltd
HAL Allergy BV
Inimmune Corp
Inmunotek SL
JiangSu Qyuns Therapeutics Co Ltd
Kolmar Korea Holdings Co Ltd
Laboratorios LETI SL
Link Health Group
Marinomed Biotech AG
Mitsubishi Tanabe Pharma Corp
Navipharm Co Ltd
Novartis AG
Oneness Biotech Co Ltd
Paradigm Biopharmaceuticals Ltd
Regeneron Pharmaceuticals Inc
Roxall Medizin GmbH
Sam-A Pharm Co Ltd
Sedor Pharmaceuticals LLC
Shouyao Holding Co Ltd
Siolta Therapeutics Inc
Stallergenes Greer plc
The Geneva Biotech Center SA
United Biomedical Inc
Vactech Oy
Wolwo Pharma
Wuhan Yicheng Biotechnology Co Ltd